Industry Report “Acute Coronary Syndrome ACS Market Research Report – Forecast to 2023” provides a clear picture of the Current Market Scenario which includes past and estimated future size with respect to value and volume, technological advancement, detail information and strategies of top key players in the industry.
The escalating stress levels have caused a sharp spike in the number of cases detected in relation to heart diseases. Market reports connected with the healthcare industry have been made accessible by Market Research Future who publishes reports on other sectors that have been currently published along with a report on this industry. The market is projected to develop with a CAGR of 10.4% in the forecast period.
On the basis of end-user, the market is segmented into academic institutes, diagnostic centers, hospitals and clinics, and others. By type, the market is segmented into Non-ST-Elevation Myocardial Infarction (NSTEMI), ST-Elevation Myocardial Infarction (STEMI), unstable angina, and others.
By diagnosis, the Acute Coronary Syndrome ACS Market is segmented into imaging, stress test, blood tests, and others. The imaging segment is further sub-segmented into Computerized Tomography (CT) angiogram, Myocardial Perfusion Imaging (MPI), coronary angiogram, echocardiogram, and others.
On the basis of treatment, the market is segmented into surgery, medication, and others. The medication segment is sub-segmented into nitroglycerin, thrombolytics, antiplatelet drugs, beta blockers, surgery, statins, and others. The antiplatelet drugs segment is further segmented into clopidogrel, aspirin, prasugrel, and others. The beta blockers segment is moreover segmented into nadolol, metoprolol, and others. The statins segment is additionally segmented into simvastatin, atorvastatin, and others. The surgery segment is sub-segmented into coronary bypass surgery, angioplasty and stenting, and others
Get Detailed Information on Global Acute Coronary Syndrome Market Research Report by Type (Unstable Angina, Nstemi), by Diagnosis (Blood Tests, Imaging, Stress Test), Treatment (Medication, Surgery), End-User (Hospitals & Clinics, Diagnostic Centers) – Global Forecast Till 2023 @ https://www.marketresearchfuture.com/reports/acute-coronary-syndrome-market-5782
Leading Market Players
The strategic competitors in the acute coronary syndrome market are Johnson & Johnson Services, Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Boehringer Ingelheim International GmbH (Germany), Portola Pharmaceuticals, Inc. (U.S.), AbbVie Inc. (U.S.), Bayer AG (Germany), AstraZeneca (U.K), Eli Lilly and Company (U.S.), Amgen Inc. (U.S.), Merck & Co., Inc. (U.S.), GlaxoSmithKline Plc. (U.K), Daiichi Sankyo Company, Limited (Japan), Sanofi (Paris), Novartis AG (Switzerland), and others.
Related NewsAcute Myeloid Leukemia Market Outlook
About Market Research Future:
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.